Skip to main content


Access to Medicine Index

Johnson & Johnson rises to second place in ranking of global companies’ efforts to advance access to healthcare 

We’re advancing global access to healthcare

Improving worldwide access to healthcare and tackling some of the world’s most devastating and neglected diseases helps give everyone the opportunity to lead a healthy life.

We’re proud that Johnson & Johnson’s actions to expand access to our medicines and focus on addressing diseases that disproportionately impact people in lower- and middle-income countries has ranked the company second in the 2022 Access to Medicine Index.

Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time we are featured as a top three performer by the Index.

The Access to Medicine Index

The Access to Medicine Index is a biennial report card that grades the world’s largest pharmaceutical companies on their efforts to advance access to medicines in lower- and middle-income countries. Since the previous ATMI was published, Johnson & Johnson has continued to raise the bar to drive impact, marking milestones, including:

  • Supporting the vaccination of more than 200,000 people and strengthening local health systems through a groundbreaking campaign with the Government of Rwanda.
  • Launching the Johnson & Johnson Centers for Global Health Discovery, a network of research partnerships around the world aimed at tackling entrenched and emerging health challenges, including TB, antimicrobial resistance (AMR) and dengue.
  • Investing $100 million to help found the $1 billion AMR Action Fund, which aims to bring two- to-four new antibiotics to patients by 2030.
  • Committing $15 million, via the J&J Foundation, to the Africa Frontline First Catalytic Fund to help build a health workforce across 10 countries in Africa.